Search

everythinglearnresearchcommunity

for

Search:↓

A 22-year-old male experiencing hair thinning and loss, possibly due to seborrheic dermatitis or low vitamin D, is cautious about using minoxidil or finasteride due to heart palpitations and high blood pressure. Suggestions include using ketoconazole shampoo to control inflammation and focusing on treating the dermatitis first.

A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.

An 18-year-old male with hair loss is considering starting finasteride but is concerned about potential side effects like gynecomastia due to his prolactin levels. He seeks guidance on whether his bloodwork indicates it's safe to begin treatment.

User deciding between oral and topical minoxidil, concerned about hypertrichosis and myocarditis interaction. They're using topical finasteride, LLLT, natural oils, dermastamping, and scalp massage, and considering adding oral minoxidil.

The conversation is about a user who had a hair transplant with 2,850 grafts and switched from finasteride and topical minoxidil to oral minoxidil and dutasteride for better results. They are hopeful for full results in a year.

The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.

A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.

Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

A potential update on the progress of pyrilutamide, a hair loss treatment; and if Kintor should stop their trials.

The user tried a product labeled as PP405 from Umbrella Labs for hair loss but saw no changes, and it was revealed to be a fake or misidentified product. The user is also using finasteride, minoxidil, and other treatments but is still experiencing hairline issues.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

Pyrilutamide is being considered as an additional treatment to Minoxidil and Dutasteride for hair loss. Users report mixed results, with no evidence of it worsening hair loss.

The user experienced a panic attack after adding 5% topical minoxidil to their routine, which already included oral finasteride and minoxidil, and microneedling. They are seeking advice on whether microneedling increased absorption and if the anxiety attacks will subside.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

RU58841 alone had mixed results; some users combined it with minoxidil. One user experienced side effects with finasteride and maintained with RU58841 and minoxidil, but noted possible chest pain.

A 20-year-old male is experiencing worsening diffuse thinning despite using topical minoxidil, topical finasteride with minoxidil, oral finasteride, stemoxydine, and pyrilutimide. He is seeking support and advice as he struggles with the mental and physical challenges of hair loss treatments.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hair follicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.

A 29-year-old male experienced hair regrowth using minoxidil 5% foam and KX826 after stopping finasteride due to side effects. He applies both treatments once daily and reports no side effects from the current regimen.

The user experienced significant hair thinning despite using finasteride and minoxidil, leading to concerns about whether it's a temporary shed or a more serious issue. They plan to start using RU58841 and are advised to consult a doctor to rule out other causes like autoimmune disorders.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.

Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.

The user has been on finasteride and minoxidil since 2020 and increased dutasteride and minoxidil doses in June 2024, but still experiences hair loss. Despite trying pyrilutamide without success, opinions vary on whether the hair loss is significant, with some suggesting it might be due to lighting, angles, or a regular shedding cycle.

The user mixed RU58841 with Minoxidil for hair loss treatment and experienced reduced hair fall and thicker hair but stopped due to chest pain and muscle twitching. They plan to use a new routine without RU58841 or Finasteride due to side effects, including various topical treatments and peptides.